SuperworthKaryopharm Therapeutics shares outstanding KPTI
Diluted shares outstanding, averaged over each quarter, from 2013.
- Latest quarter, to Jun 30, 2026
- 28.9M
- On a year earlier
- +235.7%
- more shares
Karyopharm Therapeutics had 28.9M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 235.7% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 17.9M | +113% |
| FY2024 | 8.4M | +10% |
| FY2023 | 7.7M | +28% |
| FY2022 | 6M | +19% |
| FY2021 | 5M | +3% |
| FY2020 | 4.9M | +15% |
| FY2019 | 4.3M | +5% |
| FY2018 | 4.1M | +25% |
| FY2017 | 3.2M | +18% |
| FY2016 | 2.8M | +16% |
| FY2015 | 2.4M | +9% |
| FY2014 | 2.2M | +92% |
| FY2013 | 1.1M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 28.9M | +236% | |
| Q1 FY26 | 24.7M | +192% | |
| Q4 FY25 | 17.9M | +113% | |
| Q3 FY25 | 8.7M | +4% | |
| Q2 FY25 | 8.6M | −16% | |
| Q1 FY25 | 8.5M | +10% | |
| Q4 FY24 | 8.4M | +10% | |
| Q3 FY24 | 8.3M | +9% | |
| Q2 FY24 | 10.3M | +35% | |
| Q1 FY24 | 7.7M | +2% | |
| Q4 FY23 | 7.7M | +28% | |
| Q3 FY23 | 7.6M | +43% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Karyopharm Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.